RecallRadar

FDA Drug recall D-0492-2024

Clorazepate Dipotassium Tablets, USP, 7.5 mg, a) 100 tablets per bottle, NDC 13107-283-01, b) 500 tablets per bottle, NDC 13107-283-05, Rx…

On 2024-05-15 the FDA classified a Class II recall of Clorazepate Dipotassium Tablets, USP, 7.5 mg, a) 100 tablets per bottle, NDC 13107-283-01, b) 500 tablets per bottle, NDC 13107-283-05, Rx… by Aurobindo Pharma Usa, citing discoloration: Dotted and yellow spots on tablets.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0492-2024
ClassificationClass II
Statusongoing
Initiated2024-04-24
Published2024-05-15
Last updated2026-09-13 11:52 UTC
CompanyAurobindo Pharma Usa
DistributionUS

Product

Clorazepate Dipotassium Tablets, USP, 7.5 mg, a) 100 tablets per bottle, NDC 13107-283-01, b) 500 tablets per bottle, NDC 13107-283-05, Rx Only, Distributed by Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India.

Reason

Discoloration: Dotted and yellow spots on tablets

Identifiers

ndc13107-282-01
ndc13107-282-05
ndc13107-283-01
ndc13107-283-05
ndc13107-284-01
code_infoLot #s: a) CZB124001B, CZB124002B, CZB124003B, Exp. 12/31/2025; b) CZB124001A, CZB124003A, Exp. 12/31/2025.

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0492-2024%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.